Barclays analyst Matt Miksic lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $51.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Tandem Diabetes Care (TNDM) PT Lowered to $13 at Wells FargoAugust 7, 2025 7:52 AM Tandem Diabetes Care (TNDM) PT Lowered to $16 at BairdAugust 7, 2025 7:51 AM Nephron Downgrades Tandem Diabetes Care (TNDM) to HoldAugust 7, 2025 7:30 AM Tandem Diabetes Care (TNDM) PT Lowered to $14 at Truist SecuritiesAugust 7, 2025 7:01 AM Tandem Diabetes Care (TNDM) PT Lowered to $16 at MizuhoAugust 7, 2025 6:44 AM Tandem Diabetes Care (TNDM) PT Lowered to $24 at Canaccord GenuityAugust 7, 2025 6:36 AM Tandem Diabetes Care (TNDM) PT Lowered to $10 at CitiAugust 7, 2025 5:15 AM Piper Sandler Downgrades Tandem Diabetes Care (TNDM) to NeutralAugust 7, 2025 1:10 AM Form 10-Q TANDEM DIABETES CARE For: Jun 30August 6, 2025 4:24 PM Form 8-K TANDEM DIABETES CARE For: Aug 06August 6, 2025 4:18 PM Tandem Diabetes (TNDM) Misses Q2 EPS by 38c, provides guidanceAugust 6, 2025 4:15 PM Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual GuidanceAugust 6, 2025 4:05 PM Tandem Diabetes Care (TNDM) PT Lowered to $17 at Bernstein SocGen GroupAugust 6, 2025 7:51 AM